Answers are grounded in this paper and cite their sources.
Background and Objective: There has been little advancement in the management of resectable non-small cell lung cancer (NSCLC) regarding neoadjuvant and adjuvant setting for almost two decades.
No takes yet. Share an insight, caveat, or question.
Dragana Jovanović (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: